海角社区

The institute that developed the 鈥淢ontreal Procedure鈥� continues to be on the cutting edge

The Neuro is recognized worldwide as a leader in epilepsy research and treatment. From the beginning, Neuro founder, Dr. Wilder Penfield, made epilepsy a central focus. He and his colleagues developed a surgical treatment for epilepsy patients known as the 鈥淢ontreal Procedure,鈥� which today is in use throughout the world. The Neuro became a pioneer in studying epilepsy through the use of electroencephalography (EEG) and magnetic resonance imaging (MRI).

Women scientists and clinicians are creators and changemakers, expanding the boundaries of human knowledge

听

The Neuro has launched Neuro XXceptional - an exciting new year-long video series featuring women who tell us what drove them to become scientists and clinicians, and what they love about their work. At The Neuro, these exceptional professionals are improving the lives of patients, helping us understand how the brain works and how to treat neurological disease.

You鈥檙e about to turn 60, and you鈥檙e fretting. Your mother has had Alzheimer鈥檚 disease since the age of 65. At what age will the disease strike you? A Canadian study published in JAMA Neurology shows that the closer a person gets to the age at which their parent exhibited the first signs of Alzheimer鈥檚, the more likely they are to have amyloid plaques, the cause of the cognitive decline associated with the disease, in their brain.

Volume in brain region linked to physiological changes characteristic of AD

New research has drawn a link between changes in the brain鈥檚 anatomy and biomarkers that are known to appear at the earliest stages of Alzheimer鈥檚 disease (AD), findings that could one day provide a sensitive but non-invasive test for AD before cognitive symptoms appear.

Industry and academia team up for the benefit of people suffering from ALS

A unique industry-academia partnership will increase the rate at which promising drug compounds can be tested as potential treatments for amyotrophic lateral sclerosis (ALS), a disease with no known cure that affects 200,000 people worldwide.

The partnership between The Montreal Neurological Institute and Hospital (MNI) and Takeda Pharmaceutical Company Limited (Takeda) will allow compounds developed by Takeda scientists to be tested on cell lines produced at the MNI.

Grants for Heather Durham, Stefano Stifani and Jay Ross total just over $2 million听

Three MNI researchers have received grants from the ALS Society of Canada worth a total of more than $2 million. 听

The Azrieli Centre for Autism Research will foster innovations in therapy and a better understanding of Autism Spectrum Disorder.

A new research centre in Montreal will help lift the shroud of mystery surrounding autism spectrum disorder (ASD), and lead to the development of better diagnostic tools and more effective therapies for people with autism.